a physician a building location a clinical trial a department
BCM - Baylor College of Medicine

Giving life to possible

Parkinson's Disease Center and Movement Disorders Clinic

Essential Tremor (ET)

Tremor, an oscillatory movement produced by rhythmic contractions of muscles, is the most common form of involuntary movement, but only a small fraction of those who shake seek medical attention. Essential tremor (ET) is the most common form of tremor, affecting about 5 percent of people over the age 60 years. Although ET is more common in the elderly and is often wrongly labeled as "senile tremor" it may start at any age. Studies have shown that there is a bimodal distribution of age at onset with peaks in the 2nd and 6th decades. In contrast to rest tremor, which is most frequently secondary to Parkinson's disease, ET is typically an action-postural tremor. Patients usually first become aware of the tremor when they are holding newspapers or utensils or when reaching for objects. ET can also affect the neck muscles producing either "yes-yes" or "no-no" oscillation of the head. When the vocal cords are affected the patient experiences tremulous voice while singing or talking. A review of the clinical features in 350 consecutive patients diagnosed with ET referred to the Movement Disorders Clinic at Baylor College of Medicine has shown that hands are involved in 90 percent of all ET patients, head in 41 percent, voice in 17 percent, and legs in 14 percent. Despite the frequently used prefix "benign" ET can produce significant physical and psychosocial disability. In addition to social embarrassment, ET can interfere with writing, eating, speaking, singing and various other activities of daily living. Although the tremor frequency tends to decrease with age, the amplitude usually increases and the tremor may become more and more troublesome.

In some cases, tremors occur only during a particular task, such as writing, or while holding limbs in certain position such as when bringing a glass to the mouth. These task-, and position-specific tremors are considered variants of ET, but in some cases the clinical features overlap with another movement disorder, called dystonia. Dystonia is manifested an involuntary sustained contraction of muscles producing abnormal movements or postures. Examples of dystonia include writer's cramp, torticollis or wry neck (cervical dystonia), and involuntary eye closure (blepharospasm). In some patients, dystonia produces rhythmical movements resembling ET, but in contrast to ET, dystonic tremor is more irregular and is more influenced by the position of the affected body part. Some studies have suggested that there is an association between ET and dystonia, and between ET and Parkinson's disease. This is supported by the reports of well-studied families in which some members have typical ET, while others have dystonia, parkinsonism or a combination of all three disorders. Furthermore, some patients start with typical ET and several years or decades later develop associated parkinsonism or dystonia, or both. Although it should not be difficult to differentiate tremor of ET and tremor typically seen in patients with PD, the occasional co-existence of the two disorders in the same individual may present a diagnostic challenge. In addition to dystonia and parkinsonism, patients with ET seem to have a higher frequency of deafness, hereditary neuropathy, mild incoordination and loss of balance. Orthostatic tremor is a fast tremor, involving mainly legs and trunk. It is present chiefly on standing and may be associated with a feeling of unsteadiness and calf cramps, relieved by sitting or by assuming a supine position.


Frequently misdiagnosed as a stress-related condition or a natural consequence of aging, ET is actually a manifestation of a genetic neurological disorder. Family history of tremor is present in the vast majority of patients. Despite the overwhelming evidence that ET is a genetic disorder, the gene or genes for ET have not yet been fully identified. Although at least six gene loci for familial ET have been identified, there is currently no DNA test for ET Imaging studies are usually normal. Recent evidence points to two types of associated pathology. The more frequent is the loss and swelling of specialized cells called Purkinje cells in the cerebellum ,the brain area responsible for coordination. In some cases, brainstem Lewy bodies, pathological features usually found in Parkinson's disease, are seen. Interestingly, the LINGO1 gene variant, which has been associated with increased risk of ET, has also been implicated in Parkinson's disease. Considering the overlapping clinical and pathological features of the disorders, there is ongoing debate over if the diseases share a common pathogenesis. Although not caused by stress, both physical and emotional duress can exacerbate ET, as can an overactive thyroid and certain drugs. The role of environmental exposures in ET is just starting to be explored. Recently, a link between increased blood levels of the environmental neurotoxin, harmane, a beta-carboline alkaloid, and ET has been discovered, though the etiological importance of this finding is unclear.


The treatment of tremor depends largely on its severity; many patients require nothing more than simple reassurance. Most patients who are referred to a neurologist, however, have troublesome tremors that require pharmacologic or surgical treatments. The large amplitude and slow frequency postural tremors usually do not respond well to pharmacologic therapy. Since alcohol reduces the amplitude of ET in about 2/3 of patients, some patients use it regularly for its "calming" effect and some use it before an important engagement where the presence of tremor could be a source of embarrassment. Regular use of alcohol to treat ET is inadvisable. Propranolol (Inderal), a beta-adrenergic blocker, remains the most effective drug for the treatment of ET and enhanced physiologic tremors, but other beta blockers may also ameliorate postural tremor. The major side effects of propranolol and other beta blockers, include fatigability, sedation, depression and erectile dysfunction. These drugs are contraindicated in the presence of asthma and insulin-dependent diabetes.

The anti-tremor effect of primidone (Mysoline) has been confirmed by several clinical trials. By starting at a very low dose the occasional acute, toxic, side effects (nausea, vomiting, sedation, confusion and loss of balance) of primidone can be prevented. A combination of the two drugs, propranolol and primidone, may be more efficacious than either drug alone.

In addition to beta blockers and primidone, the benzodiazepine drugs, such as lorazepam (Ativan) and clonazepam (Klonopin) also may also improve ET and its variants. Gabapentin (Neurontin), topiramate (Topamax), and pregabalin (Lyrica), drugs approved for the treatment of epilepsy, may be also useful in the treatment of tremors. Gabapentin, levodopa, primidone, clonazepam, and phenobarbital may be useful in patients with orthostatic tremor, a possible variant of ET. Patients with head tremor do not usually respond to medications, but can be effectively treated with botulinum toxin (BTX) injections into the neck muscles. BTX is also effective in the treatment of hand tremor. Usually well tolerated, BTX can produce transient weakness of the injected muscles.

Neurosurgical treatments, such as deep brain stimulation (DBS), are generally reserved for patients whose tremors continue to interfere with work or activities of daily living despite optimal medical therapy. DBS involves an incision in the scalp and drilling a hole in the skull. The surgeon then uses a "probe," a wire electrode, and advances the electrode into the portion of the brain that is thought to be functioning abnormally. The DBS lead, which actually contains four electrodes, is surgically inserted into the desired target and fixed to the skull with a ring and cap. An extension wire passes from the scalp area under the skin to the chest and is connected to a totally implantable pulse generator (IPG), a pacemaker-like device, which can deliver pulses with a variety of parameters, modes, and polarities into the target brain area. The IPG is placed under the skin in the upper chest area near the collar bone. The patient can activate or deactivate the DBS system by placing a hand-held device over the chest area that contains the IPG. The major advantage of DBS over the traditional ablative procedures is that the stimulating electrodes and parameters (frequency of stimulation, pulse width, and voltage) can be adjusted to the needs of the individual patients. Potential risks, such as hemorrhage, stroke or infection, are rare, but should be considered when making a final decision about this treatment option. Side effects, if they occur, are usually reversible, but may include weakness, speech and swallowing difficulties, and abnormal sensations.


International Essential Tremor Foundation 
PO Box 14005
Lenexa, KS 66285-4005 
Phone: (913) 341-3880
Toll free: (888) 387-3667 
Fax: (913) 341-1296 
Email: info@essentialtremor.org

Selected References

Benito-León J, Louis ED, Bermejo-Pareja F. Neurological Disorders in Central Spain Study Group. Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80:423-5.

Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004;292:1685-6.

Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson’s disease. Neurology. 2005;65:651-2.

Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130:1456-64.

Deng H, Gu S, Jankovic J. LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand. 2012;125(1):1-7.

DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010;25:232-8.

Elble RJ. Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord. 2006;21:2052-61.

Erer S, Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007;109:784-5.

Fahn S, Jankovic J. Principles and Practice of Movement Disorders, Churchill Livingstone, Elsevier, Philadelphia, PA, 2007:1-652. (Accompanied by a DVD of movement disorders.)

Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: A randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285:195-7.

Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009;11:293-307.

Hou JG, Jankovic J. Botulinum toxin in the treatment of tremors. In: Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Williams & Wilkins, Philadelphia, PA, 2002:323-36.

Jankovic J. Essential tremor: A heterogenous disorder. Mov Disord. 2002;17:638-44.

Jankovic J, Ondo WG, Stacy MA, et al. A multicenter, double-blind, placebo-controlled trial of topiramate in essential tremor. Mov Disord. 2004;19 (Suppl 9):S448-9.

Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114:1203-5.

Jankovic J, Noebels JL. Genetic mouse models of essential tremor: Are they essential? J Clin Invest. 2005;115:584-6.

Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders, 5th ed., Lippincott Williams and Wilkins, Philadelphia, PA, 2007:1-720. (Accompanied by a CD video atlas.)

Jankovic J, Shannon KM. Movement disorders. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. Neurology in Clinical Practice, 5th ed., Butterworth-Heinemann (Elsevier), Philadelphia, PA, 2008.

Kenney C, Simpson R, Hunter C, Ondo W, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106:621-5.

LaRoia H, Louis ED. Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence? Neuroepidemiology. 2011;37(1):1-10.

Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology. 2008;31:139-49.

Louis ED, Benito-León J, Bermejo-Pareja F. Population-based study of baseline ethanol consumption and risk of incident essential tremor. J Neurol Neurosurg Psychiatry. 2009;80:494-7.

Louis ED1, Zheng W. Beta-carboline alkaloids and essential tremor: exploring the environmental determinants of one of the most prevalent neurological diseases. Scientific World Journal. 2010;10:1783-94.

Lyons K, Pahwa R, Comella C, Eisa M, Elble R, Fahn S, Jankovic J, Juncos J, Koller W, Ondo W, Sethi K, Stern M, Tanner C, Tintner R, Watts R. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26:461-81.

Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61:1093-7.

Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58:218-22.

Ondo W, Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16:1137-42.

Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27:274-7.

Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13:67-76.

Sheffield JK, Jankovic J. Botulinum toxin in tic disorders and essential hand and head tremor. In: Truong D, Dressler D, Hallett M, eds. Manual of Botulinum Toxin Therapy, Cambridge University Press, 2009:195-204.

Spanaki C, Plaitakis A. Essential tremor in Parkinson's disease kindreds from a population of similar genetic background. Mov Disord. 2009;24:1662-8.

Stacy MA, Elble RJ, Ondo WG, Wu SC, Hulihan J; TRS study group. Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. Mov Disord. 2007;22:833-8.

Additional Information